Earnings summaries and quarterly performance for Viatris.
Executive leadership at Viatris.
Board of directors at Viatris.
DS
David Simmons
Detailed
Director
EF
Elisha Finney
Detailed
Director
FD
Frank D’Amelio
Detailed
Director
HK
Harry Korman
Detailed
Director
JM
James M. Kilts
Detailed
Director
JL
JoEllen Lyons Dillon
Detailed
Director
LG
Leo Groothuis
Detailed
Director
MP
Mark Parrish
Detailed
Vice Chair of the Board
MH
Melina Higgins
Detailed
Chair of the Board
MS
Michael Severino
Detailed
Director
RM
Rajiv Malik
Detailed
Director
RM
Richard Mark
Detailed
Director
RV
Rogério Vivaldi Coelho
Detailed
Director
WD
W. Don Cornwell
Detailed
Director
Research analysts who have asked questions during Viatris earnings calls.
David Amsellem
Piper Sandler Companies
8 questions for VTRS
Also covers: ABBV, ALKS, AMGN +27 more
Jason Gerberry
Bank of America Merrill Lynch
6 questions for VTRS
Also covers: ALKS, AMPH, ARWR +23 more
UR
Umer Raffat
Evercore ISI
6 questions for VTRS
Also covers: ALKS, AMGN, BHC +15 more
AV
Ashwani Verma
UBS Group AG
5 questions for VTRS
Also covers: ACAD, ALKS, ALVO +14 more
CS
Christopher Schott
JPMorgan Chase & Co.
5 questions for VTRS
Also covers: ABBV, AMGN, AMRX +15 more
MD
Matt Dellatorre
Goldman Sachs
5 questions for VTRS
AV
Ash Verma
UBS
3 questions for VTRS
Also covers: ACAD, ALVO, AVDL +8 more
BP
Balaji Prasad
Barclays
2 questions for VTRS
Also covers: ALVO, AMRX, ELAN +7 more
CS
Chris Schott
JPMorgan Chase & Company
2 questions for VTRS
Also covers: ABBV, AMGN, BIIB +10 more
DD
Dennis Ding
Jefferies Financial Group Inc.
2 questions for VTRS
Also covers: ARDX, CARA, CRNX +9 more
GS
Glen Santangelo
Jefferies
2 questions for VTRS
Also covers: ALGN, ANIP, BHC +16 more
JG
Jason Gerbery
Bank of America
2 questions for VTRS
Also covers: IONS
LS
Les Sulewski
Truist
2 questions for VTRS
Also covers: BHC, CRMD, PCRX +1 more
LS
Leszek Sulewski
Truist Securities
2 questions for VTRS
Also covers: AKBA, AMRX, ANIP +6 more
J
JP
Evercore ISI
1 question for VTRS
LW
Li Wenwen
Danasting
1 question for VTRS
Recent press releases and 8-K filings for VTRS.
Viatris reports Q4 2025 results and 2026 guidance
VTRS
Earnings
Guidance Update
Product Launch
- Viatris posted Q4 revenues of $3.7 billion, up 1% year-over-year (ex-India), and full-year 2025 revenues of $14.3 billion (+2% vs. 2024 ex-India), with adjusted EBITDA of $4.2 billion and adjusted EPS of $2.35.
- The company is guiding to ~2% revenue and EBITDA growth in 2026, including $450 million–$550 million from new product launches, and expects to have >$2.5 billion in cash available for deployment.
- An enterprise-wide strategic review is expected to deliver $650 million of gross cost savings (net $400 million after up to $250 million reinvestment) over three years, split evenly between SG&A and COGS improvements.
- Pipeline catalysts in 2026 include anticipated regulatory decisions for six product candidates (e.g., EFFEXOR for GAD in Japan, low-dose estrogen patch in the US) and an NDA submission for fast-acting meloxicam by end-February.
- In 2025, Viatris returned > $1 billion to shareholders via dividends and share repurchases, underscoring its balanced capital-allocation approach.
1 day ago
Viatris reports Q4 and full-year 2025 results
VTRS
Earnings
Guidance Update
Share Buyback
- Viatris delivered Q4 2025 revenues of $3.7 billion (up 1% operationally vs. Q4 2024) and FY 2025 revenues of $14.3 billion (up 2% operationally), with adjusted EBITDA of $4.2 billion, adjusted EPS of $2.35, and free cash flow of $2.2 billion (excluding transaction-related costs).
- For 2026, the company guides to ~2% total revenue and adjusted EBITDA growth, underpinned by a $650 million gross cost-savings program (net $400 million after up to $250 million of reinvestment) phased over 2026–2028.
- Anticipated new product revenues of $450 million–$550 million in 2026, driven by launches such as EFFEXOR for GAD in Japan, low-dose estrogen weekly patch in the US, and fast-acting meloxicam, alongside multiple regulatory decisions this year.
- In 2025, Viatris returned over $1 billion to shareholders via dividends and share repurchases, generated $2.2 billion of free cash flow, and plans debt paydowns to target a 2.8×–3.2× leverage ratio.
1 day ago
Viatris reports Q4 2025 results and 2026 guidance
VTRS
Earnings
Guidance Update
- Q4 2025 total revenues were $3.704 B, up 5% year-over-year (1% operational); adjusted EBITDA was $1.003 B (+2%) and adjusted EPS was $0.57 (+6%).
- Free cash flow in Q4 was $619 M (or $730 M ex transaction costs), an increase of 81% (7% ex costs) vs prior year.
- 2026 guidance midpoint assumes total revenues of $14.7 B (+3%), adjusted EBITDA of $4.3 B, adjusted EPS of $2.40, and free cash flow ex transaction and restructuring costs of $2.15 B.
- The company expects to realize ~30% of $400 M net cost savings in 2026 and advance its Phase 3 pipeline with readouts starting in 2026, targeting operational growth across all regions.
1 day ago
Viatris reports Q4 2025 results and 2026 outlook
VTRS
Earnings
Guidance Update
Product Launch
- Reported Q4 total revenue of $3.7 billion (up 1% ex-indoor impact) and full-year 2025 revenue of $14.3 billion (up 2% ex-indoor), with Adjusted EBITDA $4.2 billion, EPS $2.35, and free cash flow $2.2 billion; returned over $1 billion to shareholders via buybacks and dividends.
- 2026 guidance calls for approximately 2% total revenue and Adjusted EBITDA growth versus 2025, underpinned by an enterprise strategic review expected to yield $650 million in gross cost savings (net $400 million after up to $250 million reinvestment) over three years.
- Pipeline milestones in 2026 include regulatory decisions for six candidates—Effexor (GAD in Japan), pitolisant, fast-acting meloxicam, low-dose estrogen patch, Ryzumvi (presbyopia), Inpefa—and multiple Phase III readouts with full enrollment in cenerimod and soladragrom trials.
- Completed an enterprise-wide strategic review to optimize cost structure, enhance operational efficiency, and modernize technology, data, and talent capabilities, positioning Viatris for sustained growth beginning in 2026.
- Nashik, India oral solid dose facility temporarily shut after a mid-February fire; operations expected to resume in April with impact already factored into 2026 guidance.
1 day ago
Viatris reports Q4 and full-year 2025 results
VTRS
Earnings
Guidance Update
Cash Flow
- Q4 revenues of $3.70 billion, up 5% reported and 2% on a divestiture-adjusted operational basis vs. Q4 2024.
- Q4 GAAP net loss of $340 million (EPS $(0.30)) vs. net loss of $517 million (EPS $(0.43)) in Q4 2024; adjusted EBITDA of $1.0 billion (+2% reported, +1% divestiture-adjusted) and adjusted EPS of $0.57 (+6% reported, +2% divestiture-adjusted).
- Q4 operating cash flow of $816 million and free cash flow excluding transaction costs of $730 million.
- Full-year revenues of $14.30 billion (net sales $14.25 billion), GAAP net loss of $3.51 billion and adjusted EPS of $2.35; free cash flow of $1.94 billion.
- 2026 guidance: revenues $14.45–$14.95 billion, adjusted EBITDA $4.15–$4.45 billion, adjusted EPS $2.33–$2.47, free cash flow excl. transaction- and restructuring-related costs $1.95–$2.35 billion.
1 day ago
Viatris reports Q4 and full-year 2025 financial results
VTRS
Earnings
Guidance Update
- Q4 total revenues of $3.7 B (up 5% reported; 2% operational) and full-year 2025 total revenues of $14.3 B (down 3% reported; 1% operational)
- Q4 GAAP net loss of $(340 M) vs. $(517 M) year-ago and adjusted EPS of $0.57 (+6%); FY GAAP net loss of $(3.5 B) and adjusted EPS of $2.35 (down 11%)
- Generated free cash flow of $619 M in Q4 and $1.94 B for the year, returning over $1 B to shareholders in 2025
- Provided 2026 guidance: total revenues of $14.45–$14.95 B, adjusted EBITDA of $4.15–$4.45 B, and adjusted EPS of $2.33–$2.47
1 day ago
Idorsia reports strong 2025 results with QUVIVIQ sales more than doubling
VTRS
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Idorsia's 2025 net revenue reached CHF 221 million, up from CHF 113 million in 2024.
- QUVIVIQ sales more than doubled to CHF 134 million in 2025, fueling improved margins.
- US GAAP operating loss narrowed to CHF 33 million (vs CHF 232 million in 2024); non-GAAP operating loss of CHF 100 million (vs CHF 308 million).
- 2026 guidance targets CHF 200 million in QUVIVIQ sales and expects a non-GAAP operating loss of roughly CHF 120 million.
- Key pipeline catalysts in 2026 include a Q2 readout for pediatric insomnia (daridorexant) and advancement of the lucerastat registrational study in Fabry disease.
2 days ago
Viatris files sNDA for phentolamine solution for presbyopia
VTRS
Product Launch
- FDA has accepted Viatris’s supplemental NDA for MR-141 (phentolamine ophthalmic solution 0.75%) for presbyopia, assigning a PDUFA goal date of October 17, 2026.
- The sNDA is supported by pivotal Phase 3 trials (VEGA-2 and VEGA-3), both of which met primary and all key secondary endpoints with no treatment-related serious adverse events.
- Ryzumvi® (phentolamine ophthalmic solution 0.75%), currently approved for pharmacologically-induced mydriasis, would expand to include presbyopia upon approval.
- Global licensing agreement with Opus Genetics grants Viatris exclusive U.S. commercialization rights for phentolamine ophthalmic solution.
3 days ago
Viatris partner Mapi Pharma to present Phase II PPMS data at ACTRIMS Forum 2026
VTRS
Product Launch
New Projects/Investments
- Mapi Pharma will present new safety and efficacy data from its GA Depot Phase II study in primary progressive multiple sclerosis (PPMS) at ACTRIMS Forum 2026, February 5–7 in San Diego.
- The open-label Phase IIa trial enrolled 30 PPMS patients treated with 25 mg (n=10) or 40 mg (n=20) intramuscular GA Depot every 28 days for up to three years.
- Results showed stable or improved mean EDSS (from 5.1 to 4.5 at three years) and a 96.6% confirmed disability progression–free rate; 69% of patients had no evidence of progression.
- GA Depot was generally well tolerated, with most adverse events (81.6%) being mild (injection site reactions, asthenia, fever), and lower AE rates at the 25 mg dose.
- Following Israeli and EU GMP approval, a Phase III PPMS study is planned for 2026, with potential commercial launch in relapsing MS in 2027 under Viatris’ exclusive license.
Feb 3, 2026, 3:00 PM
Viatris launches Inpefa in UAE
VTRS
Product Launch
- Viatris launched Inpefa (sotagliflozin) in the UAE, the first country in its territories to commercialize the dual SGLT1/2 inhibitor for heart failure treatment.
- Inpefa, approved to reduce cardiovascular death, hospitalization for heart failure and urgent heart failure visits in adults with heart failure, type 2 diabetes, chronic kidney disease or other cardiovascular risk factors, is the first and only dual SGLT1/2 inhibitor for heart failure.
- Approval was based on Phase 3 trials: SOLOIST-WHF showed a 33% reduction in the composite risk of heart failure hospitalization, urgent visits and cardiovascular death (up to 51% when initiated pre-discharge); SCORED showed a 25% reduction in the same endpoint; MACE was reduced by 23%, MI by 32% and stroke by 34%.
- Viatris plans additional launches over the next several years and has submitted regulatory filings in Canada, Australia and Mexico to expand global access.
Jan 20, 2026, 11:59 AM
Fintool News
In-depth analysis and coverage of Viatris.
Quarterly earnings call transcripts for Viatris.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more